Capgemini Life Sciences and Healthcare’s Post

📢 There are just a few weeks to go now to ACHEMA 2024. I will be presenting on a topic that is driving significant innovation in our industry - "AI in Pharma: Digital Twins as Growth Factor. 📅 Date: Monday 10th June, 11:00 - 11:20 CEST 📍 Location: ACHEMA 2024, Siemens Stage, hall 11 In this session, we'll explore how digital twins are revolutionizing the pharmaceutical sector by enabling enhanced data-driven decision-making, optimising processes, and accelerating drug development timelines. We’ll delve into: 🔹 The integration of AI and digital twin technology 🔹 Real-world applications and case studies 🔹 Future trends and opportunities for growth Join me to discover how these advancements are not only transforming our industry but also paving the way for groundbreaking developments in healthcare. Looking forward to connecting with industry leaders and innovators at ACHEMA 2024! Let's shape the future of pharmaceuticals together. 💡💊 #ACHEMA2024 #Pharmaceuticals #DigitalTwins #AI #Innovation #Healthcare #DrugDevelopment #FutureOfPharma #TechnologyToTransformTheEveryday

What are you most excited to learn about at this year's Disruptive Technology for Clinical Trials Summit? Ahead of his session in Boston, MA, USA on 8 October, we were thrilled to speak with Alex Sverdlov, Senior Director, Statistical Scientist, Novartis to find out what he’s looking forward to most at this year’s edition. From current digital technologies and platforms trends, decentralized clinical trials, and emerging regulatory perspectives, Alex is looking forward to uniting with industry leaders from top pharma organizations to debate and discuss top strategies to Accelerate Clinical R&D, Connectivity, and Patient-Centric Outcomes. Be a part of the discussion and save 25% by registering with 4THJULY2025 today*: https://lnkd.in/eMg3JacE *Offer ends 10 July 2024. Exclusions apply. Cannot be combined with other offers. Email info@amg-world.co.uk for more info. #Disruptivetechnology #ClinicalTrials #StatisticalScience #DrugDevelopment #Innovation #AMGWorld #DisruptiveClinicalTrials

🚀 𝐀𝐯𝐚𝐥𝐥𝐚𝐧𝐨 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐏𝐫𝐨𝐭𝐨𝐜𝐨𝐥𝐂𝐨𝐩𝐢𝐥𝐨𝐭: 𝐀𝐈-𝐏𝐨𝐰𝐞𝐫𝐞𝐝 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐫𝐨𝐭𝐨𝐜𝐨𝐥 𝐀𝐬𝐬𝐢𝐬𝐭𝐚𝐧𝐭 #Avallano has unveiled 𝐏𝐫𝐨𝐭𝐨𝐜𝐨𝐥𝐂𝐨𝐩𝐢𝐥𝐨𝐭, an innovative AI-driven assistant designed to revolutionize how biopharmaceutical companies and clinical research sites manage complex clinical trial protocols. 𝐊𝐞𝐲 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: • 𝐀𝐈 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲: Leverages advanced AI to streamline understanding and adherence to protocols. • 𝐂𝐡𝐚𝐭𝐛𝐨𝐭 𝐈𝐧𝐭𝐞𝐫𝐟𝐚𝐜𝐞: Provides easy access to crucial protocol information, reducing reliance on cumbersome documents. • 𝐄𝐧𝐡𝐚𝐧𝐜𝐞𝐝 𝐄𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲: Allows clinical research professionals to focus on critical tasks, improving productivity and compliance. • 𝐄𝐚𝐫𝐥𝐲 𝐀𝐝𝐨𝐩𝐭𝐢𝐨𝐧: Avallano invites early partners to test and deploy ProtocolCopilot, ensuring it meets industry needs. “We are excited to bring ProtocolCopilot to the market, offering a cutting-edge solution that not only enhances efficiency but also supports compliance and accuracy in clinical research,” said 𝐏𝐚𝐮𝐥 𝐃𝐞𝐥𝐥𝐚 𝐌𝐚𝐠𝐠𝐢𝐨𝐫𝐚, CEO of Avallano. By harnessing AI, we address industry challenges and empower research professionals. #ClinicalResearch #AIInHealthcare #ProtocolCopilot #Biopharmaceuticals #HealthTech

In a recent study, the top reason why drug launches didn’t meet expectations was a lack of product differentiation, where also 56% of failed drug launches cited inadequate or incomplete understanding of the market and/or customer needs. This blog by Caju AI CEO Otavio Freire pinpoints three specific improvements for how pharma and biotech teams can ‘take back the launch.’ https://bit.ly/48vNm1X #cajuai #caju #druglaunch #productlaunch

An integral part of the existing science and technology ecosystem, it is important to understand the role of CRO’s, CMO’s & CDMO’s in the Pharma and Biotech Industry. This latest article from our specialist team discusses their significance, the difference between them and the implications for the fit out industry. We are pleased to have worked with a number of these organisations, designing and delivering facilities which allow them efficiently reach their goals. Read the article by Dr Manisha Kulkarni here: https://lnkd.in/e29g_DZ3

✨We're still buzzing from the collaborative energy of our 2nd annual Digital Day! This event, held at our Lausanne headquarters, focused on accelerating pharmaceutical development and patient access through digitalization. 🖥️   👉 From insightful discussions with top industry professionals to knowledge sharing from innovative digital health startups, we delved into the challenges and practical strategies that pharmaceutical companies should employ for sucessful digtial transformation.    As we navigate this exciting era of AI models revealing valuable insights from complex data and digital platforms that improve the patient clinical trial experience, we are more committed than ever to invest in and test new technologies to optimize our drug development process. The potential for these disruptive technologies to accelerate research into future care standards for patients is immense!✨ #DigitalHealth #PharmaceuticalDevelopment #DigitalTransformation #AIinHealthcare #ClinicalTrials

Proud to be at Merck and excited that we are part of a newly forged industry forum: the DISRUPT-DS roundtable. This roundtable brings together data science leaders across global pharmaceutical R&D to collectively shape thinking and benchmarking around the use of data science. Biopharmaceutical R&D is undergoing unprecedented change. One of the most exciting changes is the growing potential of data science, especially artificial intelligence (AI). This technology holds significant potential to enhance R&D efficiency, facilitate decision-making, drive scientific innovation, and ultimately bring new medicines to patients faster. At #Merck, we are investing in our people, data, technology and overall capabilities to drive measurable results, while not getting caught up in the hype. As a collective, the DISRUPT-DS roundtable has recently published an article in Nature Reviews Drug Discovery defining five ‘grand challenges’ for data science in pharma R&D. Read the full article here: https://lnkd.in/e2wEUg7a We look forward to continuing this important work with our valued DISRUPT-DS colleagues. James Weatherall Thomas Senderovitz Najat Khan, PhD Janice Branson, Benedikt Egersdoerfer Eric Genevois-Marlin Sreenu Prakash Sai Jasti Mustaqhusain Kazi Ranjit Kumble Jeremy Forman Patrick Loerch Justine Rochon Venkat Sethuraman Xiaoying Wu, MD,MS Ryan Copping Simon Davies Susanne Gronen Priya Chandran Madura Jayatunga Dhruv Jayanth Chris Meier

🌟In 2030, over half of FDA-approved drugs will involve AI in their development and/or manufacturing. The winner, will be the end-user who will have cheaper, safer and more effective treatments, delivered at a faster pace.🌟 It takes anywhere between 10 to 15 years and around US$ 3 billion to take a new drug from its discovery phase to the market. AI can drastically cut both the timespan and costs and bring life-saving yet affordable treatments to the market at a faster pace. Drugmakers are eager to ride the AI wave. Life sciences organisations like Bayer, Merck KGaA, Moderna, BMS, Roche, Astellas, Amgen, Eli Lilly, Sanofi, Novo Nordisk and Johnson & Johnson have announced collaborations, signed deals and entered into partnerships in the AI space Most life sciences companies have and are investing heavily into AI for early stage drug discovery, 'delivering at a faster' pace means automation and efficiency across the later stages of development including compliance across regions. What is the most exciting development you have seen with AI in life sciences? #AI #lifesciences #regulatory #pharma #FDA #regintelligence #Regask John Vause Andrew Dalton Jin X.Cary Smithson

Major pharmaceutical companies are on the collaboration pathway as reflected by 139 collaborations with AI solution providers since 2021. This is one of the key findings contained in a whitepaper titled “The Pharma’s Rush into AI” by Research2Guidance. The paper evaluates collaborations, partnerships and acquisitions made by 10 major pharma companies over the last 3 years. Key highlights include, * Pharma is driving innovations with AI-focused collaborations. * Of the 139 collaborations, AstraZenaca leads the way followed by Janssen, BMS, Bayer, and Sanofi. * 43% of these collaborations focus on drug discovery and development. * 32% focus on diagnostics and monitoring. * 14% focus on expediting clinical trials and generating insights. * Areas such as digital health, knowledge management and supply chain optimization lag behind in terms of priority and investment. The report highlights the need for a strategic approach to AI partnerships for pharma to harness the full potential offer by emerging technologies. Drug discovery is a crucial aspect for pharma, but it is worth noting that the outcomes will be evident only in the long run. To fully leverage AI's potential, pharma may need to focus on the here and now and relook at the underinvested domains like enabling digital health. #ai #pharma #drugdiscovery #innovation #digitalhealth Source: research2guidance (Link in comments)